Email Alerts
Sign up today and receive company updates straight to your inbox.
Company Overview
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 46 patents granted and many patents pending worldwide.
IR Contacts
Headquarters
Canadian Operations
#100-740 McCurdy RoadKelowna, BC V1X 2P7
US Operations
105 Peach State CourtSuite A
Tyrone, GA 30290
Investor Relations
IR contact
T: 250-765-6424 ext. 202
IR@lexariabioscience.com
Transfer Agent
Computershare Investor Services Inc.
T: 800-564-6253
https://www.computershare.com
Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.